Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice

In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates

(2019) Amit Kaushik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis

(2019) Nakwon Kwak et al.   EUROPEAN RESPIRATORY JOURNAL

In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus

(2019) Eva Le Run et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease

(2019) Sanne M. H. Zweijpfenning et al.   EUROPEAN RESPIRATORY JOURNAL

Improved activity of bedaquiline by verapamil against Mycobacterium abscessus in vitro and in macrophages

(2019) Albertus Viljoen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus

(2019) Marissa Lindman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro and intracellular activity of imipenem combined to rifabutin and avibactam against Mycobacterium abscessus

(2018) Eva Le Run et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria

(2018) Mike Marvin Ruth et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

(2017) Charles S Haworth et al.   THORAX

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

(2016) Beatriz E. Ferro et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections

(2016) Cristina Cigana et al.   Scientific Reports

Impact of β-Lactamase Inhibition on the Activity of Ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus

(2015) Vincent Dubée et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models

(2015) Andrés Obregón-Henao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease

(2015) Julie V. Philley et al.   CHEST

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

(2015) R Andres Floto et al.   THORAX

Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: The Mycobacterium abscessus model

(2015) Vincent Le Moigne et al.   VACCINE

In VivoAssessment of Drug Efficacy against Mycobacterium abscessus Using the Embryonic Zebrafish Test System

(2014) Audrey Bernut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

 -Lactamase inhibition by avibactam in Mycobacterium abscessus

(2014) V. Dubee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus

(2013) Isabelle Lerat et al.   JOURNAL OF INFECTIOUS DISEASES

Animal model of Mycobacterium abscessus lung infection

(2008) D. Ordway et al.   JOURNAL OF LEUKOCYTE BIOLOGY